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 The airway epithelium is at the interface between the host and the environment, plays a critical role 
in normal wound repair, and is implicated as key in 
the immunopathogenesis of asthma. 1 Epithelial cells 
in vivo are in an activated state, with increased expres-
sion of chemokines such as CXCL8 2 and CCL11. 3 
Structural changes observed consistently in the asth-
matic epithelium include increased permeability, 4 
reduced ciliary beat frequency and coordinated cilia 
movement, increased cell protrusion and cytoplasmic 
blebbing, 5 goblet cell hyperplasia, 6 increased mucin 
production, 7 and increased levels of epithelial prolif-
eration and apoptosis 8 when compared with nonasth-
matic epithelium. 
 Whether these abnormalities persist in vitro is 
important to determine the relative contribution of the 
asthmatic environment and intrinsic changes in cel-
lular behavior in deﬁ ning disease expression. Follow ing 
wounding, asthmatic epithelium demonstrates aber-
rant repair, dyssynchronous mitosis, 9 and defective 
epithelial tight junctions, suggesting persistence of 
abnormalities in wound repair. 10 In contrast, whether 
asthmatic epithelial cells have an enhanced synthetic 
response is contentious. Some reports have found 
 Background:  The airway epithelium plays a central role in wound repair and host defense and is 
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the synthetic capacity of epithelial cells derived from subjects with asthma and healthy control 
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or Poly-IC (Toll-like receptor 3 agonist) was measured using MesoScale discovery or enzyme-linked 
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nasal, bronchial basal, and differentiated epithelial cells but not between health and disease. 
Stimulation of the epithelial cells caused marked upregulation of most mediators, which were 
broadly corticosteroid unresponsive but attenuated by IKK2i. 
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with and without stimulation by measuring a panel 
of epithelial-derived chemokines and cytokines, 14,17,18 
and (2) to determine the effects of corticosteroids and 
novel antiinﬂ ammatory therapies upon the synthetic 
capacity of these epithelial cells. 
 Materials and Methods 
 Subjects 
 Subjects were recruited from Glenﬁ eld Hospital, Leicester, 
England and by local advertising. Asthma was deﬁ ned according 
to GINA (Global Initiative for Asthma) guidelines. 19 Subject char-
acterization included demographics, spirometry, allergen skin 
prick tests, sputum induction, methacholine bronchial challenge, 
nasal brushings, and bronchoscopy. The study was approved by 
the Leicestershire ethics committees, and all patients gave their 
written informed consent. 
 This study was conducted in accordance with the amended 
Declaration of Helsinki. The Leicestershire, Rutland, and Northamp-
tonshire ethics committee (ethics reference 4977/project approval 
number 6347) approved the protocol, and written informed con-
sent was obtained from all patients. 
 Epithelial Cell Culture 
 Epithelial cells were obtained from nasal and bronchial brush-
ings from the second- or third-generation bronchi and were grown 
on 12-well tissue culture plates in bronchial epithelial growth medium 
(BEGM; Lonza Group Ltd ), including supplement SingleQuot 
BulletKit (Lonza Group Ltd), 0.3% Fungizone antimycotic 
(Life Technologies Corporation), and 1% antibiotic-antimycotic 
(Life Technologies Corporation) for 2 to 7 days. Basal cells were 
then expanded into 75-cm 2 ﬂ asks and upon conﬂ uence seeded at 
10 5 cells/cm 2 on 1.2-cm 2 -diameter transwell clear inserts (Corning 
Incorporated) under BEGM for 2 days. All culture surfaces were 
collagen coated (Nutacon B.V.). After reaching conﬂ uence, the 
basal cell monolayer was fed on the basolateral side only with air-
liquid interface media (ALI) media. This ALI media consisted 
of 50% BEGM and 50% hi-glucose minimal essential medium 
(Life Technologies Corporation) containing 100 nM retinoic acid 
(Sigma-Aldrich Co LLC), including supplements as previously 
detailed. Supplements were removed 24 h prior to experiments. 
Nasal and bronchial basal epithelial cells were characterized using 
immunoﬂ uorescence for cytokeratin 5 and 14 expression (Abcam plc). 
Spontaneous mucus production occurred from 14 to 21 days, sug-
gesting the presence of goblet cells, and ciliation occurred between 
25 and 35 days. There was a 100% success rate of nonasthmatic 
and asthmatic cultures from the initial brushing to the passage into 
ALI and a 58% success rate of these ALI cultures becoming cili-
ated. Differentiated bronchial epithelial cells were characterized 
using high-speed video microscopy for the presence of active cilia 
 Mediator Analysis 
 Mediators from basal and differentiated epithelial cells were 
analyzed using both multiplex and single enzyme-linked immuno-
sorbent assay (ELISA) kits. We measured IL1 b , tumor necrosis 
factor (TNF)- a , CCL2, CXCL8, CXCL10, CCL11, CCL13, CCL17, 
CCL22, and CCL26 (MesoScale Discovery [MSD]; Meso Scale 
Diagnostics, LLC). Limits of detections were 2.4 to 10,000 pg/mL. 
ELISA kits analyzing single mediators were used to exam ine 
CCL5 (R&D Systems, Inc) and IFN- b (Pestka Biomedical 
Lab oratories, Inc) production from epithelial cells. Limits of detec-
tion for the CCL5 and IFN- b ELISAs were 31.2 to 1,000 pg/mL 
and 25 to 2,000 pg/mL. 
constitutive chemokine and cytokine release by epi-
thelial cells from subjects with asthma compared with 
healthy control subjects is upregulated, 11 downregu-
lated, 12 or unchanged. 9 Similarly, both an increased 13 
and deﬁ cient 14 interferon (IFN)- b response following 
exposure of epithelial cells from subjects with asthma 
to virus is reported. The phenotype of epithelial cells 
may also vary throughout the airway tree as demon-
strated by differences in transepithelial resistance 
between epithelial cells from conducting airways and 
the nose. 13 Therefore, the synthetic function of asth-
matic epithelium from different sites within the air-
way and their response to antiinﬂ ammatory therapy 
need to be further deﬁ ned. 
 Inﬂ ammatory gene expression often involves the 
transcription factor nuclear factor  k B (NF- k B), and 
this signaling pathway represents a site for antiinﬂ am-
matory intervention. Phosphorylation of the inhibitory 
 k B (I k B) proteins by the I k B kinase (IKK) 2-containing 
IKK complex and subsequent degradation of the I k B 
proteins are prerequisites for NF- k B activation. There-
fore, inhibition of IKK2 would speciﬁ cally prevent 
NF- k B transcription and signaling. One of the mech-
anisms of action of glucocorticosteroids also involves 
targeting the NF- k B pathway, and glucocorticoids are 
the most effective antiinﬂ ammatory treatments for 
asthma. 15 Although the response to these compounds 
has been well characterized in inﬂ ammatory cells within 
the airway, there is a lack of data examining the response 
to glucocorticosteroids in primary epithelial cells. 16 
 We, therefore, hypothesized that synthetic capacity 
would be altered in primary airway epithelial cells 
from subjects with asthma vs healthy subjects and 
that there would be differential effects of antiinﬂ am-
matory therapy. To test our hypothesis, we aimed to 
examine: (1) the synthetic function of airway epithe-
lial cells from different locations in health vs disease 
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 Study Protocol 
 The compounds IKK2i (100 nM, 300 nM, 1  m M, or 3  m M), 
(gifts from GlaxoSmithKline, Stevenage, England), prednisolone 
(10 nM, 100 nM, 1  m M, 10  m M) (GlaxoSmithKline) were added 
where appropriate to cell cultures for 1 h before the addition of any 
stimulus. Stimuli used included Poly-IC (0.5, 2.5, 12.5, 25  m g/mL) 
(InvivoGen) with Poly-dIdC (0.5, 2.5, 12.5, 25  m g/mL) (Sigma-
Aldrich Co LLC) as a negative control, IL-1 b (10 ng/mL) or IL-1 b 
(10 ng/mL) and IFN- g (10 ng/mL) (R&D Systems). Nasal epithe-
lial basal cells were used only to obtain a dose response to prednis-
olone and poly IC. Bronchial epithelial basal and differentiated 
cells were then used to examine the response to the full panel of 
compounds/stimuli. Epithelial basal cells were cultured on 24-well 
culture plates, and compounds/stimuli were added to the media. 
Differentiated epithelial cultures were cultured on transwells with 
compounds/stimuli added basolaterally. Cell culture superna-
tants were collected from all experiments after 24 h. Mediator 
concentrations were corrected for the volume of growth medium 
and cell count for each condition. Cell viability was assessed using 
trypan blue. 
 Statistical Analysis 
 Statistical analysis was performed using GraphPad Prism 4 
(GraphPad Software, Inc). Constitutive levels of mediators were 
log normally distributed and, thus, expressed as geometric mean 
(95% CI). Therefore, stimulated levels of mediators were expressed 
as fold change over constitutive levels. Paired and unpaired data 
were analyzed using paired and unpaired  t tests, respectively. 
Comparison across groups was assessed using analysis of variance 
(ANOVA). Differences were considered signiﬁ cant when  P   .05. 
Correction for multiple comparisons was not conducted. 20 
 Results 
 The clinical characteristics of the subjects with asthma 
and healthy control subjects are as shown in e-Table 1. 
The patterns of cytokine and chemokine expression 
constitutively released over 24 h by nasal, basal bron-
chial, and differentiated ALI culture bronchial epi-
thelial cells were signiﬁ cantly different for IFN- b , 
IL-1 b , CCL2, CCL5, and CXCL8 (e-Table 2,  Fig 1 ). 
These differences between cell types were similar for 
cells derived from subjects with and without disease, 
but no differences were observed between subjects 
with asthma and control subjects (e-Figs 1a-1c, 
e-Table 3). No differences were found between sub-
jects who were treated with corticosteroids and those 
who were corticosteroid naive (data not shown). 
 There was a concentration-dependent release of 
mediators by nasal basal epithelial cells in response 
to poly-IC activation compared with the Poly-dIdC 
control as illustrated in e-Fig 2. The concentration of 
Poly IC that induced maximal mediator release above 
constitutive levels in nasal basal cells was then used 
to stimulate bronchial basal and differentiated cells. 
Stimulation of the epithelial cells by poly IC, IL-1 b 
or IL-1 b , and IFN- g signiﬁ cantly increased medi-
ator levels above constitutive levels for the majority of 
mediators, and the pattern of mediator release was 
distinctive for the stimulus and epithelial cell type 
( Tables 1-3 ) . Differences were only observed in four 
of the 111 parameters measured between nonasth-
matic and asthmatic groups in any of the cell types 
examined (e-Tables 4-6). 
 Bronchial basal epithelial cell mediator release in 
response to Poly IC or IL-1 b and IFN- g activation 
were inhibited by IKK2i in a concentration-dependent 
manner but not by prednisolone (e-Fig 3). The addi-
tion of inﬂ ammatory stimuli and compounds did not 
affect cell viability. Prednisolone (10  m M) and IKK2i 
(1  m m) were used to assess the effect upon basal cell 
and ALI epithelial synthetic capacity. IKK2i reduced 
the release of nearly all mediators by basal and ALI 
epithelial cells in response to poly-IC, IL-1 b or IL-1 b , 
and IFN- g , and the effect was greater in basal epithe-
lial cells. Prednisolone had minimal effects upon the 
mediator release (e-Fig 4,  Tables 4-6 ). Differences 
between efﬁ cacies of the IKK2 inhibitor and pred-
nisolone were signiﬁ cant for the majority of media-
tors and stimuli for basal cells (e-Table 7). For poly 
IC-stimulated ALI epithelial cells, differences between 
the efﬁ cacy of the IKK2 inhibitor and prednisolone 
were signiﬁ cant for CCL11, CXCL10, CCL2, CCL4, 
CCL5, ( P  , .001), CCL17 ( P  , .01), and CCL26 and 
CCL22, ( P  , .05) (e-Table 8 ). 
 Discussion 
 We report here for the ﬁ rst time, to our knowledge, 
differences in the constitutive production of chemo-
kines and cytokines in vitro between nasal basal, bron-
chial basal, and bronchial differentiated epithelial cells, 
highlighting the importance of the location of the air-
way epithelium in relation to its mediator production. 
We were unable to demonstrate differences in the 
constitutive release of mediators from epithelial cells 
derived from subjects with asthma vs healthy control 
subjects from any of the epithelial cell types. There 
was marked up-regulation in mediators in response 
to proinﬂ ammatory cytokines and toll-like receptor 
(TLR)-3 stimulation, which was greater in nasal than 
bronchial epithelial cells. However, we did not identify 
differential response to these stimuli between health 
and disease. This increased expression was broadly 
corticosteroid unresponsive in epithelial cells from 
both subjects with asthma and healthy control sub-
jects, suggesting this activation of synthetic capacity 
is via corticosteroid-insensitive pathways that are not 
disease speciﬁ c. In contrast, the release of these media-
tors was markedly attenuated by IKK2 inhibition, 
suggesting that this novel antiinﬂ ammatory therapy may 
have potential to modulate corticosteroid-unresponsive 
pathways in asthma. 
 The view that intrinsic differences persist in vitro 
between epithelial cells from subjects with asthma 
vs healthy control subjects is controversial. Here we add 
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 Figure 1. Constitutive mediator concentration between primary epithelial cell types. Constitutive 
expression (pg/mL/10 6 cells) after 24 h of mediators from nonasthmatic and asthmatic nasal basal (white), 
bronchial basal (gray), and bronchial differentiated (black) epithelial cells. Cytokines are ordered accord-
ing to the statistical difference of mediators between cell types (* P   .05) (n  5 6 nasal basal, n  5 17 
bronchial basal, and n  5 21 bronchial differentiated epithelial cells). IFN  5 interferon; TNF  5 tumor 
necrosis factor. 
to this debate, as our data were unable to identify 
differential expression of a broad range of chemokines 
or cytokines from primary epithelial cells in health 
compared with disease either constitutively or fol-
lowing stimulation. 
 Deﬁ ciency in type 1 and 3 IFNs following viral 
infection in asthma is proposed to be a fundamental 
impairment in the innate immune response promot-
ing persistence of a viral infection and the develop-
ment of an exacerbation of asthma. 14,21 This deﬁ cient 
response may be in part due to chronic airway inﬂ am-
mation in asthma or due to intrinsic differences in 
asthmatic epithelium. However, we and others 13 were 
 Table 1— Mediator Concentration Between Primary Epithelial Cell Types Following Poly IC Stimulation 
Mediators 
Poly IC (12.5  m g/mL) Stimulated Epithelial Cells, Fold Change Over Constitutive Levels
 P ValueNasal Basal (n  5 6) Bronchial Basal (n  5 17) Bronchial Differentiated (n  5 17)
IFN- b 3.1 (1.0-9.6) a 4.8 (2.2-10.6) b 1.1 (0.9-1.5)  , .01 c 
CCL5 534.6 (274.0-1043.0) b 994.6 (549.3-1801.0) 42.6 (14.5-125.3) b  , .01 b,c,d 
IL-1 b 35.5 (11.1-111.3) b 2.5 (1.4-4.4) e 2.8 (1.1-7.1) a  , .01 a,d,f
CXCL8 25.9 (13.1-51.2) b 4.7 (2.51-8.9) 2.1 (1.5-2.7) b  , .01 b,c,d,f 
CCL2 52.5 (23.7-116.2) b 8.0 (3.0-21.2) 6.4 (2.7-15.2) b .02 b,d,f
CCL13 18.3 (10.8-30.8) b 5.7 (1.7-19.5) e 1.7 (1.3-2.2) b  , .01 b,c,d 
CCL4 485 0.0 (219.6-1071.0) b 135.1 (50.1-364.8) 18.1 (6.8-48.3) b  , .01 b,c,d
TNF- a 145.3 (41.1-513.1) b 11.1 (6.3-19.5) 5.0 (2.4-10.3) b  , .01 b,d,f
CCL22 25.0 (14.4-43.5) b 5.2 (2.3-11.6) 2.2 (1.7-2.9) b  , .01 b,c,d,f
CCL17 65.2 (28.0-151.7) b 10.7 (2.7-41.9) e 2.9 (2.1-3.9) b  , .01 b,d,f
CCL26 131.5 (29.4-588.6) b 4.7 (1.0-21.7) 2.5 (1.3-4.9) e  , .01 d,e,f
CXCL10 376.2 (134.8-1050.0) b 168.9 (35.7-799.5) b 48.9 (21.2-112.7) b .07 b 
CCL11 29.5 (15.6-55.7) b 10.7 (5.2-22.1) b 5.9 (3.1-11.5) b .02 b,d
Fold change (geometric mean [95% CI]) over constitutive levels after stimulation for 24 h. ANOVA  5 analysis of variance; IFN  5 interferon; 
TNF  5 tumor necrosis factor.
a P   .05 compared with constitutive levels.
b P  , .001 compared with constitutive levels.
 c Bronchial basal vs bronchial differentiated, one-way ANOVA with Tukey post hoc multiple comparison.
 d Nasal vs bronchial differentiated, one-way ANOVA with Tukey post hoc multiple comparison.
e P   .01 compared with constitutive levels.
 f Nasal vs bronchial basal, one-way ANOVA with Tukey post hoc multiple comparison.
unable to conﬁ rm this ﬁ nding in vitro. Taken together, 
these data suggest that the interferon release by epi-
thelial cells is heterogeneous, and although this abnor-
mality in innate immunity may be important in some 
individuals, it is unlikely to represent a deﬁ n ing char-
acteristic of asthma. 
 Interestingly there was a differential synthetic capa-
city of epithelial cells from different locations and 
states of differentiation. This was particularly apparent 
for IFN- b , CCL5, IL-1 b , CXCL8, and CCL2. These 
may represent important functional differences in 
wound repair and host defense. In addition to these 
differences in constitutive mediator release, there 
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were key differences in release following stimulation. 
For example, CCL2 has been implicated in wound 
repair and recruitment of monocytes 22,23 and ﬁ bro-
cytes 24 ; its release was increased constitutively, and 
following stimulation by IL-1 b there was marked 
up-regulation of release by the differentiated epithe-
lial cells compared with increased release by nasal-
derived basal cells following stimulation with poly-IC. 
IFN- b was increased in nasal and bronchial basal cells 
constitutively compared with differentiated cells. Simi-
larly, there was a generalized increase in most chemo-
kines and cytokines in the nasal epithelial basal cells 
following Poly IC stimulation compared with the bron-
chial epithelial cells. This perhaps suggests a height-
ened sensitivity of these cells to TLR3 activation, 
which may be a consequence of epigenetic changes 
promoted by previous exposure to viruses. These dif-
ferences have hitherto been unexplored and highlight 
 Table 2— Mediator Concentration Between Primary Epithelial Cell Types Following IL-1 b Stimulation 
Mediators
IL-1 b (10 ng/mL) Stimulated Epithelial Cells, Fold Change Over Constitutive Levels
 P ValueNasal Basal (n  5 6) Bronchial Basal (n  5 11) Bronchial Differentiated (n  5 10)
IFN- b 1.2 (0.6-2.6) 0.9 (0.7-1.2) 1.0 (0.8-1.1) .39
CCL5 1.9 (0.9-3.8) 9.2 (3.4-25.1) a 11.7 (3.3-41.0) b .06 b 
IL-1 b N/A N/A N/A N/A
CXCL8 10.0 (2.0-51.6) c 3.8 (1.8-7.8) b 1.9 (1.2-3.0) c .02 c,d 
CCL2 2.0 (1.6-2.4) a 1.4 (0.6-3.3) 23.2 (5.4-99.5) a  , .01 a,d,e 
CCL13 1.8 (1.4-2.4) b 3.2 (0.5-21.5) 1.7 (1.1-2.5) c .57 c 
CCL4 9.6 (3.6-25.5) b 4.2 (1.7-10.7) b 19.1 (4.6-79.8) b .14 b 
TNF- a 4.3 (1.9-9.6) b 2.7 (1.9-3.8) a 6.4 (2.1-18.8) b .19 b 
CCL22 2.0 (1.5-2.8) b 1.5 (1.0-2.3) 2.4 (1.8-3.2) a .11 a
CCL17 1.6 (1.3-2.0) b 2.1 (0.5-9.2) 2.6 (2.0-3.5) a .67 a
CCL26 2.2 (1.7-2.7) a 1.5 (0.1-16.0) 2.0 (0.7-5.4) .90
CXCL10 2.1 (1.6-2.7) a 3.3 (0.6-18.1) 6.0 (3.6-10.2) a .28 a
CCL11 2.3 (1.9-2.8) a 1.4 (1.0-2.0) 5.3 (1.6-17.7) c .07 c
Fold change (geometric mean [95% CI]) over constitutive levels after stimulation for 24 h. N/A  5 not applicable. See Table 1 legend for expansion 
of abbreviations.
a P  , .001 compared with constitutive levels.
b P   .01 compared with constitutive levels.
c P   .05 compared with constitutive levels.
 d Nasal vs bronchial differentiated, one-way ANOVA with Tukey post hoc multiple comparison.
 e Bronchial basal vs bronchial differentiated, one-way ANOVA with Tukey post hoc multiple comparison.
 Table 3— Mediator Concentration Between Primary Epithelial Cell Types Following IL-1 b and IFN- g 
Mediators
IL-1 b (10 ng/mL)  1 IFN- g (10 ng/mL) Stimulated Epithelial Cells, Fold Change Over 
Constitutive Levels
 P ValueNasal Basal (n  5 6) Bronchial Basal (n  5 17) Bronchial Differentiated (n  5 11)
IFN- b 0.7 (0.4-1.2) 0.9 (0.7-1.3) 0.9 (0.7-1.1) .60
CCL5 8.1 (2.4-27.6) a 46.6 (19.0-114.2) b 50.2 (18.5-136.1) b .07 b
IL-1 b N/A N/A N/A N/A
CXCL8 30.5 (10.3-89.7) b 4.4 (2.4-7.8) b 1.9 (1.1-3.1) c  , .01 c,d,e
CCL2 39.1 (15.5-98.4) b 63.5 (25.6-157.3) b 73.8 (15.9-342.3) b .78 b
CCL13 19.4 (7.8-48.0) b 6.4 (2.2-18.4) a 4.3 (2.9-6.5) b .11 b
CCL4 87.8 (38.5-68.0) b 42.7 (15.0-121.4) b 65.1 (19.7-214.5) b .64 b
TNF- a 5.3 (3.6-7.9) b 4.4 (3.1-6.2) b 5.6 (1.6-19.2) c .85 c
CCL22 14.3 (6.3-32.5) b 6.4 (3.3-12.4) b 6.9 (5.0-9.7) b .18 b
CCL17 29.7 (9.9-88.5) b 16.1 (5.4-48.4) b 13.8 (9.3-20.6) b .56 b
CCL26 28.2 (11.7-68.0) b 6.8 (1.8-25.7) a 6.9 (3.0-16.0) b .23 b
CXCL10 390.8 (122.1-1251.0) b 323.1 (115.5-903.3) b 645.8 (253.0-1652.0) b .54 b
CCL11 30.6 (11.6-80.6) b 13.7 (8.0-23.5) b 30.3 (9.9-93.0) b .22 b
Fold change (geometric mean [95% CI]) over constitutive levels after stimulation for 24 h. See Table 1 and 2 legends for expansion of 
abbreviations.
a P   .01 compared with constitutive levels.
b P  , .001 compared with constitutive levels.
c P   .05 compared with constitutive levels.
 d Nasal vs bronchial basal, ANOVA with Tukey post hoc multiple comparison.
 e Nasal vs bronchial differentiated, ANOVA with Tukey post hoc multiple comparison.
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the potential importance of epithelial cell type in the 
study of epithelial function in asthma. 
 The concentration of prednisolone used in this 
investigation was representative of the plasma con-
centration present in subjects with severe asthma 
taking such medication. 25 It is very interesting and an 
important ﬁ nding that the corticosteroid used had 
little effect on cytokine production, in contrast to 
IKK2 inhibition. The observed corticosteroid epithelial 
relative resistance, but responsiveness toward inhibi-
tion of IKK2 in donors with and without asthma, would 
suggest that corticosteroid epithelial unresponsiveness 
is related to features of the canonical NF- k B signaling 
pathway. These data, therefore, do not support the 
view that there is an intrinsic corticosteroid unrespon-
siveness in asthmatic epithelium as a consequence of 
differential corticosteroid receptor expression, altered 
ligand afﬁ nity, or decreased corticosteroid binding to 
DNA. 26 Indeed, although IL-8 expression has been 
shown to be signiﬁ cantly repressed by dexamethasone, 
the induction of NF- k B-dependent transcription in 
primary human bronchial epithelial cells was unaf-
fected by the application of the corticosteroid, sug-
gesting that the targeting of NF- k B transcription by 
corticosteroids may represent a more minor mecha-
nism of action than has been previously believed. 27 
 There is a potential for using small molecule inhib-
itors of IKK2 to treat asthma. These compounds bypass 
problems associated with corticosteroid-resistant ther-
apy, such as reduced corticosteroid receptor expres-
sion and translocation. 28 To date, such small molecule 
inhibitors have been proven to signiﬁ cantly inhibit 
NF- k B transcription and inﬂ ammatory gene expres-
sion in primary human airway epithelial cells, 27 com-
prehensively reduce chronic pulmonary inﬂ ammation 
in murine models, 29 and inhibit pathologic features of 
airway remodelling and ameliorate airway responsive-
ness in a chronic allergen exposure model of bron-
chial asthma in mice. 30 
 The effects of the site of sampling, selection of sub-
jects, activators, and inhibitors upon mediator release 
are important to consider. Our study focused upon 
synthetic capacity of epithelial cells in vitro to deter-
mine the persistence of abnormalities in asthmatic cells 
independent of the in vivo environment. However, 
one potential criticism is that we may have failed to 
observe other important functional differences. Indeed, 
our ﬁ ndings do not exclude the possibility that there 
remain fundamental differences in epithelial cell func-
tion in asthma. Critical differences between epithe-
lial cells from asthma and health for other functional 
responses are reported for proliferation 9,31 and wound 
repair. 9 Asthma severity may also be an important fac tor, 
although we recruited subjects across the spectrum 
of asthma severity and were unable to demonstrate dif-
ferences in synthetic capacity and disease severity. 
However, our study was underpowered to fully explore 
this question, and, thus, it remains a possibility that 
disease severity may exert an important influence 
upon epithelial cell function. Although the cells were 
stimulated basolaterally, it is acknowledged that mucus 
production on the apical surface may have still inﬂ u-
enced the function of the cell culture as a whole. To 
reduce the interference of mucus production with 
the production of cytokines, mucus was removed from 
ALI cultures prior to simulation by gentle washing 
with PBS. There is also the possibility that an alterna-
tive duration of stimulation and even apical stimula-
tion of the differentiated epithelial cultures may have 
produced differences between the donors with and 
without asthma. Indeed, there is evidence to suggest 
variation in apical and basolateral secretion of media-
tors, but this may be due to the location of receptors 
for certain stimuli. 32 The IFN- g receptor is expressed 
basolaterally in both cultured airway epithelia and 
normal human airway tissue. Therefore, stimulating 
the ALI cultures from the basolateral surface allowed 
for the maximal response to be examined from the 
differentiated epithelium. Furthermore, in vitro con-
ditions may also be important determinants of func-
tional responses, such as the matrix environment may 
inﬂ uence some of the differences observed between 
reports 9,11,12 ; indeed, the effects of culture conditions 
upon the differentiation process and its dynamic dur-
ing culture could have resulted in problems regarding 
the interpretation of data. This is unlikely to have 
affected our study, as we controlled carefully the cul-
ture conditions for the epithelial cells. Samples were 
obtained from the second- or third-generation bronchi 
and cultured on collagen-coated surfaces. Spontaneous 
mucus production occurred from 14 to 21 days and 
ciliation between 25 to 35 days. Those cultures that 
did not reach the ﬁ nal stages of differentiation were 
not used for this investigation. One further potential 
criticism is that we did not undertake corrections for 
multiple comparisons. We chose not to undertake these 
corrections, as there is a debate among statisticians 
about the validity of various methods. If a Bonferroni 
correction was applied, the revised  P value for sig-
niﬁ cance would have been adjusted from  P  5 .05 to 
 P  5 .0039. 
 In conclusion, the synthetic capacity of epithelial 
cells differs between location and the degree of dif-
ferentiation, but in vitro we were unable to identify 
differential expression between health and disease, 
suggesting that activation of epithelial cells in vivo 
maybe largely a consequence of the asthmatic envi-
ronment. Activation of epithelial cells by proinﬂ am-
matory cytokines and TLR3 agonists is corticosteroid 
unresponsiveness independent of disease, but is sen-
sitive to IKK2 inhibition, suggesting that IKK2 inhib-
itors may be important novel therapies for asthma. 
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